This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The pharmaceutical industry has donated nearly $280,000 to state lawmakers and candidates in Oregon since the start of 2019, with five Republicans drawing the biggest sums.
Though Florida and five other states -- not in the Northwest -- have passed laws allowing them to seek federal approval to buy drugs from Canada, observers say the proposal is aimed at Florida.
The Food and Drug Administration is weighing whether to resume a coronavirus vaccine trial that was halted when a volunteer suffered spinal cord damage as federal health officials launch an investigation.
Given the prevailing business-centric model of American drug pricing, a COVID-19 vaccine could be budget breaking, perhaps making it unavailable to many.
Advocates say a new rule will make it harder for patients with conditions such as cancer and multiple sclerosis who rely on very expensive drugs to afford them.
At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions.
Before the midterm elections heated up, dozens of drugmakers had already poured about $12 million into the war chests of hundreds of members of Congress.
Prescription drug prices were soaring. Angry policymakers swore they’d take action. Pharma giant Merck responded by promising to address the problem voluntarily, vowing to keep price increases under the overall rate of inflation.